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1. Introduction
Given the rapid ageing of the population worldwide, global estimates of AD - generally con‐
sidered to be the commonest subtype of dementia - are expected to increase from the current
estimated 25 million to 63 million in 2030, and by 2050, a staggering 114 million [1]. Over the
last two decades in particular, significant but modest breakthroughs in pharmacological
treatment of this devastating condition have occurred. Presently, there is increasing convic‐
tion that intervention (especially disease-modifying therapy) will have to be instituted at the
earliest possible stage of the illness to confer the greatest benefit.
Prevailing clinical criteria for Mild Cognitive Impairment (MCI) have low to moderate diag‐
nostic accuracy in identifying and predicting progression to dementia. MCI is an unstable
clinical construct where some patients convert (MCI-converters) while others remain rela‐
tively stable (MCI non-converters). As observed from neuropathological and recent bio‐
marker studies, the accumulation of AD pathology (β-amyloid plaques and neurofibrillary
tangles) may precede the onset of clinical disease by as long as 20-30 years [2,3]. This sug‐
gests that functional and structural brain changes may occur prior to apparent clinical mani‐
festations of cognitive impairment (Figure 1). However, the current definition of MCI is
based primarily on clinical and neuropsychological criteria, and this may have contributed
to limited demonstration of efficacy in therapeutic and disease-modifying trials thus far.
Supplementing existing criteria with information about biomarkers may enrich the defini‐
tion of MCI This provided the impetus for the development of reliable biomarkers such as
cerebrospinal fluid (CSF), neuroimaging and blood biomarkers to complement clinical ap‐
proaches in early diagnosis and predicting progression. In support of this, the recent pro‐
posed criteria for symptomatic pre-dementia phase of AD (MCI), preclinical AD and
presymptomatic AD have included biomarkers reflecting molecular pathology, downstream
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measures of structural and functional/metabolic changes, and associated biochemical
changes in their research diagnostic armamentarium [4].
Longitudinal studies in AD subjects have also noted variability in disease progression. In
one study, 11.9% of subjects exhibit rapid cognitive decline while some remained relatively
stable [5]. Other studies that utilized parameters such as the decline in Mini Mental State Ex‐
amination (MMSE) scores [6, 7] (≥3 point decline) also reported a distinctive difference in the
clinical course between the fast-progressors and slow-progressors.
Figure 1. Clinical Continuum of Alzheimer’s disease and hypothetical biomarker model
In this chapter, we will review the body of evidence on the use of various clinical and co‐
morbid factors, alone and/or in combination with biomarkers, on predicting rapid cognitive
decline across the spectrum of cognitive impairment – defined in terms of AD progression
in MCI subjects and rapid cognitive decline in AD subjects. We will also look at longitudinal
biomarker measurements as well as their role (alone and/ in combination with clinical and
comorbid factors) in predicting cognitive decline and disease trajectories. We will discuss
the implications of current research findings to their application in clinical and therapeutic
trials. The chapter is not intended to be an exhaustive review of this burgeoning literature,
but instead to highlight integrative and potentially novel lines of inquiry.
2. Clinical and cognitive/ behavioural characteristics (table 1)
A number of socio-demographic factors and vascular risk factors have been found to increase
risk of development of AD.
Increased risk of cognitive decline in diabetes may reflect a dual pathologic process involving
both cerebrovascular damage and neurodegenerative changes. Several possible pathophysio‐
logical mechanisms may include hyperglycemia, insulin resistance [8], oxidative stress,
advanced glycation end products, and inflammatory cytokines. A shared clinicopathologic
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study alluded to the potential shared predisposition for developing amyloid in both the
pancreas and brain [9]. This is supported by a study of intranasal insulin preventing cognitive
decline, cerebral atrophy and white matter changes in mouse models [10]. Diabetes and pre-
diabetes have been found to be associated with AD progression in MCI subjects, with pro‐
gression from MCI to dementia accelerated by 3.18 years[11]. The stronger effect of pre-
diabetes on MCI conversion may be caused by high glycemic level in pre-diabetes and
increased insulin resistance [12]. Although antihypertensive therapy has been shown to be
associated with reduced rate of conversion to AD in midregional proatrial natriuretic peptide-
stratified subjects with MCI [13], there has been a paucity of data with regard to the individual
effect of hypertension on MCI-converters[14]. A non-significant trend was found for cerebro‐
vascular disease as a risk factor for MCI-converters[15]. Diabetes, hypertension and cerebro‐
vascular disease have been found to be associated with faster progression rate in dementia
[16-19]. Although mid-life hypercholesterolemia has been repeatedly shown to increase risk
of late-life dementia, there is relatively little evidence of its influence on MCI-converters and
the rate of AD decline [20].
Study variable  Population Results  Key findings 
 
Predicting AD conversion in MCI subjects 
Diabetes and pre-  302 aMCI  155 subjects had  HR 2.87 diabetes (95%CI 1.3-6.34) 
diabetes [11]  and 182 CIND  AD progression HR 4.96 pre-diabetes (95% CI 2.27  
subjects aged   -10.84)  
≥ 75 years   Accelerated progression by 3.18 years 
over 9 years 
Vascular risk factors [21]         837 MCI subjects  298 converters HR 2.04 (95% CI 1.33-3.11) 
                                                followed annually  352 stable Hypertension HR 1.84 (95% CI 1.19-2.84) 
over 5 years   Diabetes HR 1.62 (95% CI 1.00 – 2.62) 
Hypercholesterolemia HR 1.11 (95% CI 
 1.04-1.18) 
Cerebrovascular disease HR 1.60 (95% CI 
 1,03 – 2.49) 
Diabetes, baseline  257 MCI subjects MCI conversion  Diabetes HR 2.92 (95% CI 1.12-7.6) 
white matter severity, over 3 years to AD 7.05%/year    Baseline WMC severity (mild vs severe) 
baseline moderate-to-      HR 0.04 ( 95% CI 0.006-0.242) 
severe carotid stenosis and     Baseline carotid stenosis (moderate vs mild) 
carotid stenosis change [22]         HR 8.46 (95% CI 2.1-34.14) 
Carotid stenosis change HR 124.1 (95% CI  
 0.95- 16,209.68) 
Stroke [15]  121 MCI subjects MCI conversion Stroke RR 4.0 (95% CI 0.92-13.87) 
   over 3 years to AD based on 
     age strata rate 
     (per 100 person- 
     years) 
     Total 2.3  
65-69y  0 
     70-74y 0 
     75-79 3.1 
     80-84y 2.0 
Metabolic syndrome [8] 49 MCI subjects      Progression to       67.6 (95% CI 35.17 – 129.93) Rate 1000 
with metabolic         dementia      per person-years  
   syndrome and 
72 without metabolic  
syndrome 
Age [23]   97 amnestic MCI       Annual rate of     Odds ratio = 4.5 of AD progression 
88 cognitively-           progression to     Older age [exp(β)=1.11, SE(β)=0.7, WALD=4.2,  
unimpaired controls  AD                                   p=0.040] predictors of AD conversion 
followed up 
mean 38.8 mths 
Empirically weighted and 43 MCI subjects 14 subsequently  Multivariate combinations achieved 84% accuracy, 
Combined neuropsycholo-   converted to AD 86% Sn, 83%Sp in predicting AD progression 
gical battery [42] (using episodic memory, speeded executive function, recognition memory (false positives). 
 recognition memory (true positives), speed in visuospatial memory, visuospatial episodic memory 
Learning measure and            607 MCI and HC        Conversion to Low-learning, Low retention OR17.84, 95%CI 
retention measure [43]            patients in ADNI         AD at 2 years 7.37-43.10, p<0.001; Low-learning, High reten- 
                cohort divided tion OR 9.01, 95%CI2.98-27.21,p<0.001; 
                into 4 groups:  High learning, low retention OR8.48, 95%CI 
                (based on 3.45-20.86, p<0.001 
                learning and  (high learning, high retention as reference  
                retention) group) 
MISplus [44]  40MCI subjects      Conversion to OR 0.28, 95%CI 0.099-0.79)  
                   to AD at 18 At cut-off of 2, PPV 71.5%, 











Hypertension [16]  135 incident AD  Rapid decline on Systolic BP ≥160 versus <160mmHg 
   Patients in CDR-sum of boxes (controlling for other vascular variables) 
   Cache Country and MMSE using  for CDR-SB coeff X time 1.78 (95% CI 1.20-2.36) 
   Dementia  linear mixed models  for MMSE    coeff X time -2.38 (-3.23,-1.53) 
   Progression 
   Study  
Hypertension [17]  719 AD patients ADAS-cog increase   OR 6.9 (95% CI 1.5-31.1, p=0.005) 
   In multi-center by ≥1 standard 
   Trial  deviation of baseline 
     ADAS-cog score of 
    
Diabetes [18]  154 AD patients Disease progression  Crude OR 0.38 (95% CI 0.2-0.9) 
   attending Dementia of decrease of 5 pts   Multivariate OR 0.36 (95% CI 0.1-0.9) 
   center  or more on MMSE 
Cerebrovascular disease[19] 224 AD patients Decline in MMSE, No difference in vascular risk factors except 
     ADAS-cog and cerebrovascular disease (mean difference in  
     SIB difference MMSE 13.6 (-14.3—7.6); ADAS-cog 27 (-30.1- 
       -13.7); SIB 54.4 (-62.3—29.9) 
Vascular risk factors 156 AD patients AD decline Only higher LDL-cholesterol was independently 
including heart disease, living in   using generalized associated with faster cognitive decline. 
stroke, diabetes,  community estimating equa- Stratified according to APOEε4 showed higher 
hypertension), smoking,           mean age 83 y tion models total cholesterol, higher LDL, stroke and heart  
pre-diagnosis blood lipid     disease associated with faster decline. 
and LDL-C [20] 
Age  [24]   201 Caucasian Latent class Best latent trajectory model: Initial MMSE and 
                  Probable/Possible    mixture models age. Parameter estimate 0.85, p<.001 for MMSE, 
   AD subjects at         of quadratic              Parameter estimate 0.04,p =0.04 for age. 
   ADRC, Pittsburgh    trajectories includ- 
                                                                                 Ing random intercept 
                                                                                 and concomitant 
                                                                                 variables (MMSE) 
Education [27]  127 persons in Change point Prior to diagnosis, lower levels of formal education 
   Bronx Aging study models to test associated with poorer performance on memory 
   developed dementia predictions of          and verbal fluency. Accelerated decline in SRT 
   (out of 488 comm-    cognitive reserve shown by estimated annual rates of decline for 
   unity dwelling            hypothesis using 16 years, 9.5 years and 4 years of formal edu- 
   subjects)                   Buschke Selective  cation was 3.22, 2.57 and 2.03 points/year 
     Reminding Test        respectively. 
     (SRT) 
Neuropsychiatric symptoms    177 memory-clinic Rapid disease   Affective syndrome increased risk of functional 
[30]   AD outpatients progression defined   decline (HR2.0, 95%CI 1.1-3.6) AND Manic 
     as loss of ≥1 ability   syndrome (HR 3.2, 95% CI 1.3-7.5) 
     in ADL or drop of 
     ≥ 5 points on MMSE 
Pre-progression rate- 798 probable AD  Random effects Slopes of ADAScog and PSMS change for slow  
Clinician estimate of subjects from            linear regression     pre-progression smaller than fast pre-progression. 
of duration and baseline Alzheimer’s Disease to calculate             Rates of change on ADAScog slower for inter- 
MMSE [28]                 and Memory              pre-progression      mediate pre-progression group. 
   Disorders                  categories and        Slow progressors survived longer. 
                                                 Centre                      of change in ADAS- 
 cog, VSAT Time, 
 VSAT Errors, CDR 
 Sum of boxes, PSMS 
 and IADL scores 
 
Memory and executive 154 newly  Rapid progression Memory moderate deficits: HR 1.3 (95%CI: 
Functioning [45]  diagnosed AD  of ≥ 5MMSE de- 0.4-4.5); severe deficits: HR 2.3 (95%CI: 0.6- 
   Patients  crease over 2yrs 9.0). Executive functions moderate deficits: HR 
       3.5 (95%CI 0.9-13.7); severe deficits: HR 5.7 
       (95%CI 1.4-23.2)   
HR = Hazards ratio; PPV = Positive predictive value
95% CI= 95% confidence interval; NPV= Negative predictive value
WMC= White matter severity; MMSE =Mini Mental State Examination
RR= Relative risk; SIB = Severe Impairment Battery
OR= Odds ratio
Table 1. Clinical and cognitive/ behavioural characteristics in predicting AD conversion in MCI patients and rapid AD
progression/ decline
Vascular risk factors, as a composite entity, have been shown to be associated with MCI
conversion [21]. The individual risk factors of hypertension, diabetes, cerebrovascular disease
and hypercholesterolemia in the study were associated with high risk of MCI conversion.
Treatment of hypertension, diabetes and hypercholesterolemia showed reduced risk of MCI
conversion. In the same Chongqing study, the authors showed separately the association of
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diabetes, baseline white matter changes (WMC), baseline moderate-to-severe carotid stenosis
and carotid stenosis change during follow-up to be predictors of MCI conversion [22]. A
separate longitudinal community study (ILSA- Italian Longitudinal Study on Aging) showed
MCI progression to AD of 2.3 per 100 person-years with stroke as the only vascular risk factor
associated with progression [15].
The heterogeneity of AD syndrome is likely related to, other than amyloid and tau pathology,
a number of other factors, such as impaired energy metabolism, oxidative stress, neuro-
inflammation, insulin and insulin growth factor (IGF) resistance, and insulin/ IGF-deficiency.
These factors are often included as variables of interest in studies attempting to develop
diagnostic and therapeutic targets for this disease. Brain insulin resistance promotes oxidative
stress, reactive oxygen species (ROS) generation, DA damage and mitochondrial dysfunction,
all of which drive pro-apoptosis, pro-inflammatory and pro-AβPP-Aβ cascades. Also,
hyperinsulinaemia increases AβPP-Aβ and inflammatory indices in the brain, also promoting
formation of advanced glycation end-products which lead to increased generation of ROS. Tau
gene expression and phosphorylation are also regulated by insulin and IGF stimulation, where
brain insulin and IGF resistance may result in decreased signaling through phosphoinositol-3-
kinase (PI3K), Akt and Wnt/β-catenin and increased activation of GSK-3β – which is partly
responsible for tau hyperphosphorylation. Hence, the focus on vascular factors in AD is
justified based on chronic hyperglycemia, hyperinsulinemia, oxidative stress, advanced
glycation end-products and inflammation promoting vascular disease [8].
The metabolic syndrome defined by the Third Adults Treatment Panel of the National
Cholesterol Education Program as a combination of three or more of the following compo‐
nents: abdominal obesity (waist circumference >102cm for men and >88 cm for women;
elevated plasma triglycerides (≥150mg/dl); low HDL cholesterol (<40mg/dl for men and
<50mg/dl for women); high blood pressure (≥130/ ≥85mmHg) or being in hypertensive
treatment; and high fasting plasma glucose (≥110mg/dl). This represents a clustering of
vascular risk factors for morbidity and mortality. In addition, these factors may interact
synergistically to influence cognition in a negative manner. Among MCI patients the presence
of metabolic syndrome independently predicted an increased risk of progression to dementia
over 3.5 years of follow-up. [23]
Older age has been shown to predict MCI-converters [24]. Latent class modeling methods and
disease system analysis approach to characterize trajectories of cognitive decline in AD cohorts
have also shown initial MMSE and age to best predict decline [25,26]. However, separate
studies using AD clinical trial data with subjects on Donepezil have shown younger age to
predict faster decline in placebo-treated patients [27]. Low education is a risk factor for AD.
The cognitive reserve hypothesis predicts that persons with higher education delay the onset
of accelerated cognitive decline; however, once AD disease process begins, it takes a more
rapid course due to increased disease burden [28]. Pre-progression rate (calculated using
clinician’s standardized assessment of symptom duration in years and baseline MMSE) has
also been shown to predict cognitive decline trajectory [29]. Neuropsychiatric symptoms have
also been shown to predict faster cognitive and functional decline [25,30,31].
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Prospective studies of amnestic MCI (a-MCI) subjects have shown that episodic memory (such
as delayed recall of word lists [32-34], spatial short term memory and visual recognition memory
[35], and paired-associates learning [36,37]), semantic memory [37,38], attentional processing
[39] and mental speed consistently predicted MCI converters. Within a very mild cognitive
impairment group, higher CDR-sum of boxes and lower executive function predicted AD
conversion [40].  Similarly,  in a  retrospective study of  MCI-converters,  verbal  and visual
memory, associative learning, vocabulary, executive functioning and other verbal tests of
general intelligence were impaired at baseline [41]. An empirically weighted and combined set
of  neuropsychological  tests  involving  domains  of  episodic  memory,  speeded  executive
functioning, recognition memory (false and true positives), visuospatial memory processing
speed, and visual episodic memory together were strong predictors of MCI conversion to AD
[42]. A recent study demonstrated that MCI individuals with learning deficits on the Rey
Auditory Verbal Learning test showed widespread pattern of gray matter loss at baseline, as
compared to retention deficits which was associated with more focal gray matter loss. Howev‐
er, impaired learning had modestly better predictive power than impaired retention, highlight‐
ing the importance of including learning measures in addition to retention measures when
predicting outcomes in MCI subjects [43]. Verbal cued recall measured using the Memory
Impairment Screen plus (MISplus) has also been shown to predict MCI conversion [44].
In subjects with AD, rapid disease progression was noted more frequently in subjects with
higher education and those with moderate severity of global impairment. More severe memory
impairment and executive dysfunctioning were associated with higher probabilities of
progression at 2 years [45].
Longitudinally, follow-up of those who developed AD versus those who were non-demented
prior to AD diagnosis, showed no evidence for accelerated decline of episodic memory from
6 to 3 years prior to incident dementia diagnosis [46]. Working memory (using digit span
backward and forward as well as digit ordering) also did not show temporal change as a
potentially useful marker of progression [47].
2.1. Summary
Age, vascular risk factors and metabolic syndrome affect AD conversion in MCI subjects.
However, there is currently a lack of data on the effect of intensive vascular risk factor
treatment in delaying/ halting the rate of progression in MCI subjects. Educational attainment
plays an interesting role in AD. In support of the cognitive reserve hypothesis, higher educa‐
tional attainment predicts delay of the onset of accelerated cognitive decline; however, once
AD disease process begins, it takes a more rapid course due to increased disease burden.
Neuropsychological tests, especially episodic memory and executive functioning tests, seem
to predict MCI-converters. When assessing MCI subjects, the inclusion of impaired learning
in addition to retention measures may improve predictive power of AD progression from MCI.
More severe cognitive impairment is associated with rapid AD progression.
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3. Cerebrospinal fluid biomarkers (tables 2)
The most widely studied candidate CSF biomarkers include CSF total tau (t-tau), 42 amino
acid form of Aβ (Aβ1-42) and phosphorylated tau protein (p-tau) [48]. They reflect respectively
the corresponding central pathogenetic process of neuronal degeneration, amyloid-β peptide
deposition in plaques, and hyperphosphorylation of tau with subsequent tangle formation.
Fagan et al has also recently demonstrated that CSF Aβ and tau protein measurements,
performed using INNOTEST enzyme-linked immunosorbent assay (ELISA) and INNO-BIA
AlzBio3, were highly correlated with brain amyloid load, as assessed by PET and Pittsburgh
compound B amyloid-imaging (r value from 0.77 to 0.94)[49]. This was further suggested, by
a study of antemortem CSF concentrations of Aβ1-42 and t-tau/ Aβ1-42 ratio in an autopsy-
confirmed AD cohort, that the standardization of biomarker techniques could potentially
replace autopsy-confirmed AD for future diagnosis of definite AD [50].
3.1. Established CSF biomarkers
CSF biomarkers of elevated t-tau [51-56], high p-tau [52,53,57,58], low Aβ1-42 [52,53], and
combinations of high t-tau/ p-tau and low Aβ1-42 concentrations [59-64], have been shown to
be predictive of MCI-conversion to AD. The consistent feature in all of these studies is that
increased CSF t-tau and p-tau concentrations are highly sensitive while low Aβ1-42 concentra‐
tion is more specific. A recent longitudinal study showed that subjects with the lowest baseline
Aβ42, highest tau and and p-tau concentration exhibited the most rapid MMSE decline. In
addition, while there was little difference in the levels of these CSF biomarkers between stable
MCI and cognitively healthy subjects, MCI-AD converters had the highest total tau concen‐
trations [65].
High CSF t-tau and p-tau concentration (but not Aβ42) was associated with more rapid MMSE
decline in a 3-year prospective longitudinal study. This suggests that increased t-tau levels
reflect intensity of disease and hence rapidity of AD progression, while Aβ42 is more a
diagnostic state marker, not associated with rate or stage of AD [65,66]. Another study showed
p-tau to poorly differentiate between AD and vascular dementia, but to correlate with MMSE
progression [67]. In contrast, another recent report showed lower Aβ42 levels to be associated
with rapid-progressors compared with slow-progressors [68]. Wallin et al showed that AD
subjects with a combination of low Aβ42 and very high CSF t-tau and p-tau levels performed
worse on baseline cognitive tests, with faster deterioration, poorer outcome to cholinesterase
inhibitor treatment and increased mortality [69].
With respect to serial biomarker measurements with disease progression, we found studies
showing increasing p-tau 231 levels with disease progression in MCI subjects [70, 71] com‐
pared to controls over a period of 12-24 months. No definite trends were observed with Aβ40
and Aβ42 in the same studies [70,71]. A recent longitudinal study showed that nonspecific CSF
biomarkers, in particular isoprostane, demonstrated an increase over time, which was correlat‐
ed with AD conversion in MCI subjects and cognitive decline (as assessed by MMSE) [72].
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 Study variable  Population Results  Key findings 
 
Predicting AD conversion in MCI subjects 
Combination CSF   137 MCI subjects 42% converted - t-tau >350ng/L & Aβ42 <530 ng/L: 
biomarkers [64]  compared to to AD   Sn: 95%, Sp 83% of AD conversion 
  39 healthy     HR 30, 95% CI 9.32-96.8, p<0.001 
   controls    - p-tau >60ng/L & Aβ42 <530 ng/L: 
        Sn 95%, Sp 81% of AD conversion 
        HR 26.3, 95% CI 8.16-83.4, p<0.001 
       - t-tau/ Aβ42 ratio < 6.5 (t-tau>350ng/L) 
         Sn 95%, Sp 87% of AD conversion 
         HR 32.8 (10.2-105.6,p<0.001) 
 
Predicting rapid AD progression/ decline 
CSF biomarker  142 AD subjects 35 subjects had - High levels of t-tau correlated with 
concentration  followed-up over t-tau>800ng/L lower baseline MMSE scores. 
[66]   5 years    More rapid decline in MMSE score correlated 
with higher baseline t-tau (rs=-0.23,p=008). 
- p-tau>110ng/L showed lower baseline MMSE 
scores but no difference in progression. 
- Aβ42 showed no difference in baseline scores 
or progression. 
CSF p-tau  70 AD and VD  Cognitive decline 58% of probable AD patients showed p-tau  
concentration  subjects with assessed 12 mth concentration higher than 36.08ng/L. 
[67]   36 age-matched (MMSE ≥ 5 point Cognitive decline correlated with p-tau conc- 
healthy controls decline after 1yr) entration (x
2
 =12.442, p=0.001). 
CSF Aβ42  74 AD subjects Rapid progressors Lower Aβ42 CSF concentration (mean 292 pg/ 
concentration    defined at MMSE ml) in fast-progressors compared to slow- 
[68]     decline >4/years progressors (mean 453 pg/ml) (p=0.042) 
 
Low CSF Aβ42  151 AD subjects k-means cluster Cluster 3 performed poorer on baseline 
and high CSF    analysis done. cognitive tests. They exhibited poorer outcome 
t-tau and p-tau     Cluster 1 low Aβ42 of cholinesterase inhibitor treatment. Cognition 
levels     and low t-tau, p-tau deterioriated faster over time with substantially 
[69]     Cluster 2 low Aβ42 increased mortality rate. 
and intermediate 
t-tau, p-tau 
Cluster 3 low Aβ42 
and high t-tau, p-tau 
HR = Hazards ratio
CRP = C-reactive protein
MMSE =Mini Mental State Examination
OR = Odds ratio
Sn = Sensitivity
Sp= Specific
LR+ = positive Likelihood ratio
LR - = negative Likelihood ratio
HR = Hazards ratio
95% CI= 95% confidence interval
Table 2. Cerebrospinal fluid biomarkers in predicting AD conversion in MCI patients and rapid AD progression/
decline
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Faster progression of brain atrophy (in terms of regional cortical thinning) has been found in
the presence of lower Aβ1-42 levels and higher p-tau in Alzheimer’s Disease Neuroimaging
Initiative (ADNI) data [73].
3.2. Novel CSF approaches
In a study in which novel CSF biomarkers were identified through mass spectrometry and re-
evaluated by ELISA, it was found that NrCAM, YKL-40, chromogranin A and Carnosinase I
were potentially able to improve the diagnostic accuracy of existing Aβ42 and tau CSF
biomarkers. This could potentially improve characterization of clinic-pathological stages of
the cognitive continuum from cognitive normalcy to mild dementia, with the promise of
potential utility in clinical trials and monitoring disease progression [74]. Other potential CSF
biomarkers include nanoparticle-based amyloid-β-derived diffusible ligands (ADDLs)[75], as
well as a multiplexed immunoassay panel of a combination of a subset of markers, in particular,
calbindin, which showed significant prognostic potential [76]. Preliminary data have also
shown that soluble Aβ oligomers might inhibit long-term potentiation and hence, play an
important role in AD pathogenesis. The increasing appreciation of Aβ oligomers (as compared
to its native forms) in the pathogenesis of AD may suggest novel pathways to biomarkers, such
as anti-oligomer antibodies that are specific for the soluble oligomeric state (as opposed to the
fibrillar states). By quantifying Aβ oligomer formation, anti-oligomer antibodies may provide
a promising strategy for monitoring disease progression [77,78].
Concerns with CSF biomarkers include measurement variability occurring through lack of
standardization of CSF assays [79], high inter-laboratory and between-assay variance,
sampling-handling factors, post lumbar-puncture headache, and poor acceptability to
patients, especially if repeated measurements are involved. In an attempt to overcome these,
the Alzheimer’s Association has launched a global quality-control program for AD CSF
biomarkers, which will be administrated from the Clinical Neurochemistry Laboratory in
Molndal, Sweden. This includes reference samples for use in studies, allowing normalization
of biomarker levels and meta-analyses of published papers [80].
3.3. Summary
Elevated CSF total tau, p-tau, low Aβ and high tau: Aβ concentrations have been consistently
shown to highly predict MCI-converters and AD progression. CSF Aβ and tau may reach a
plateau at a relatively early stage of disease and remain fairly constant thereafter, limiting its
utility for longitudinal measurement and in monitoring therapeutic response at the more
advanced/ established stage of AD. However, it remains an important biomarker during the
preclinical and prodromal stages of AD, reflecting the central pathogenic neurodegenerative
process. Novel CSF biomarkers hold promise of circumventing this current limitation,
especially Aβ oligomers and their potential use in documenting disease progression as well
as being a potential therapeutic target. The invasive nature of lumbar puncture and standard‐
ization issues preclude its current routine clinical use.
Predicting Cognitive Decline in Alzheimer’s Disease (AD): The Role of Clinical, Cognitive Characteristics and Biomarkers
http://dx.doi.org/10.5772/54289
383
4. Blood markers (table 3)
Peripheral blood is one of the most convenient sources of biomarkers. While the quest for a
marker with high sensitivity and specificity has been ongoing for decades, no single blood-
derived biomarker has been particularly outstanding in the diagnosis of AD, in predicting
conversion from MCI to AD and in predicting slow and fast progression. The following are
some of the most studied biomarkers. One should note that negative studies are usually not
published and hence publication bias is possible.
 
Study variable Population Results Key findings 
 
Predicting AD conversion in MCI subjects  
Αbeta   Cohort 1: 117 48 (41%) subjects No difference in plasma Abeta levels between 
Hansson [82]  MCI subjects of cohort 1 MCI subjects that subsequently developed AD 
   followed up for 4 developed AD; and HC or stable MCI subjects. 
   -7  years;  15 (14%) subjects HR (per SD decrease adjusted for age, sex): 
   Cohort 2: 110 of cohort 2 Aβ40 1.08 (0.78-1.51), Aβ42 0.95 (0.71- 
   followed up for 2 developed AD 1.27), Aβ42/42 ratio 0.83 (0.64-1.08) 
– 4 years 
Koyama [84]  Meta-analysis Summary risk Association of low plasma Abeta42/Abeta40 
 with 10,303 ratio of 1.60 and ratio with AD and dementia. 
 subjects 1.67 for AD and  
  dementia 
     respectively 
 
C Reactive Protein  168 MCI subjects 58 subjects Association of high plasma CRP level with 
[86]   followed up over developed accelerated cognitive deterioration and 
   2 years  dementia  increased risk of AD. 
       MMSE score was significantly lower 
       for patients with high CRP levels 
       than those with low CRP levels (- 
   4.9 ± 5.4 vs -3.2 ±4.2, p < 0.05) 
 
APOE [90] 35 prospective 1236 developed APOE-ε4 allele is associated with a 
 cohort studies of AD.  moderately increased risk for progression from 
 MCI subjects,   MCI to AD-type dementia. 
 including 6095   OR for MCI subjects with APOE ε4 
 subjects over 2.9   progression to AD 2.29  (95% CI 
 years of follow-up   1.88 to 2.80).Sn 0.53 (95% CI 0.4 to 0.61),  
    Sp  0.67 (95% CI 0.62 to 0.71), PPV 0.57  
    (95% CI 0.48 to 0.66), NPV 0.75 (95% CI  
    0.70 to 0.80). LR+ 1.60 (95% CI 1.48 to 1.72),  
    and LR- 0.75 (95% CI 0.67 t o0.82).  
    Meta-regression showed that Sn,Sp and 
    NPV were dependent on age, APOE-ε4 
       allele background prevalence or follow-up length 
 
Predicting rapid AD progression/ decline 
APP isoforms in  48 AD subjects Progression of AD Association of low APPr at baseline in 
platelets [85]  followed up over   predicting cognitive decline in AD. 
   1 year    APPr <0.40, 
       ∆MMSE = -2.8 ± 3.0, p < 0.05 
       APPr ≥0.40, 


















Combination of  122 AD subjects Followed up Low plasma levels of Abeta40, Abeta42, and 
Aβ and CRP [87]    4.2 years  high-sensitivity CRP were associated with a  
       significantly more rapid cognitive decline. 
       Plasma biomarkers contributed to 5-12% variance  
    on Blessed Dementia Scale and Activities of Daily 
    Living. 
        
Ceramides [89]  120 probable AD Follow-up 2.3y Highest tertiles of DHSM/DHCer and  
subjects     SM/ceramide ratios declined1.35 points 
   (p=0.001) and 1.19 (p=0.004) less per year on 
   the MMSE and increased 3.18 points (p=0.001) 
    and 2.42 (p=0.016) less per year on ADAS-Cog. 
APOEε4   
Martins [91] 218 AD subjects In the non-linear APOE genotype strongly predicts the rate of 
  model, possession cognitive decline in AD. 
  of an APOEε4 APOEε4 homozygotes showed faster cognitive 
  allele was related decline than heterozygotes. 
  to earlier and 
  faster cognitive 
  decline. APOEε2  
  allele related 
  to slower decline. 
 
Cosentino [92] 199 population- Presence of at APOEε4 influences cognitive decline most 
 based incident least one ε4 allele significantly in the earliest stages of AD. 
   AD subjects, associated with 
 215 population- faster cognitive 
 based prevalent decline in the 
 AD subjects, 156 population- 
 clinic-based AD based incident AD 
 subjects followed group (p = 0.01). 
 up for an average However, this 
 of 4 years association is 
  absent in 
  prevalent AD 
  subjects in 
  population or clinic 
  based group. 
HC = Healthy controls
SD = Standard deviation
OR = Odds ratio
95% CI= 95% confidence interval
Sn = Sensitivity
Sp= Specificity
OR = Odds ratio
PPV = Positive predictive value
NPV= Negative predictive value
LR+ = positive Likelihood Ratio
LR- = negative Likelihood Ratio
Table 3. Blood biomarkers in predicting AD conversion in MCI patients and rapid AD progression/ decline
4.1. Plasma proteins/ peptides
Teleologically the most logical candidate is plasma Amyloid-beta (Aβ) and its derivatives,
Aβ40 and Aβ42. They are the most studied of blood markers.
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As Aβ accumulation is an early step in AD pathogenesis, such a biomarker would be poten‐
tially suitable for identifying patients in the earliest stage of disease process when intervention
might be more effective.
Circulating Aβ is composed of Aβ produced by brain and peripheral tissue, and can be
transported across the blood-brain barrier. They are derived from the amyloid precursor
protein (APP). APP is catabolized via 2 pathways, one of which is amyloidogenic, and involves
3 enzyme systems, alpha, beta and gamma secretases. In the amyloidogenic pathway, APP is
first cleaved by beta secretase to generate a secreted form of APP (sAPPbeta) and a C99
fragment. The C99 is then cleaved by gamma secretase to yield Aβ. Different cleavage sites on
the C99 fragment produces two forms of Aβ – Aβ40 and Aβ42. While Aβ40 is the more common
product, Aβ42 aggregates into amyloid fibrils more rapidly and is contained in both early
diffuse plaques and fully formed neuritic plaques. In the non-amyloidogenic pathway, alpha
secretase is involved and does not lead to Aβ formation [81].
Since elevation appears to be before or just at the onset of the clinically diagnosed disease, it
has been hypothesized that high plasma Aβ42 is an antecedent risk indicator for AD, and its
plasma levels declines with onset and progression. There have been many studies involving
Aβ40 and Aβ42, though results have been inconclusive and at times contradictory refer to
Table 1 [82, 83]. These inconsistent results may reflect variability due to technical reasons, such
as timing of sample collection with reference to AD onset, the assay methods, and differential
affinities of the antibodies used for different Aβ species. Koyama [84], in a large systematic
review, concluded that plasma levels of Aβ40 and Aβ42 individually were not associated with
development of AD and dementia. However the ratio of Aβ42:Aβ40 could predict development
of AD and dementia, although the evidence is limited in MCI conversion and AD progression.
APP isoforms in platelets have been suggested to predict cognitive decline. APP metabolism
has been found to be altered in the platelets of AD patients, specifically a reduced ratio of the
upper (130kDa) to the lower (110-106 kDa) immunoreactivity band (APPr) [85].
The level of plasma C-reactive protein (CRP) rises in response to inflammation. Its role is
primarily to activate the complement system. CRP by itself has been reported to be associated
with accelerated cognitive deterioration and increased risk of conversion in MCI patients [86].
A combination of raised CRP with low Aβ has been associated with a significantly more rapid
cognitive decline [87].
Homocysteine has been reported to be associated with human disease states, notably cardio‐
vascular disease. Deficiencies of the B vitamins – B6(pyridoxine), B9(folic acid) and B12(coba‐
lamin) are associated with high homocysteine levels. However, there is no data on
homocysteine with MCI conversion and AD progression.
Clusterin, also called apolipoprotein J and coded by gene CLU, has been reported in genome-
wide association studies (GWAS) to be associated with AD [83]. Clusterin is functionally
associated with apoptosis and the clearance of cellular debris, including amyloid. Thambie‐
setty [88] found that higher clusterin levels were associated with slower brain atrophy in
normal subjects who developed MCI during a 6-year follow-up. However, there is no current
data with MCI conversion and AD progression.
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Ceramides are a family of lipid molecules that are made up of sphingosine and a fatty acid.
They are also constituent of sphinomyelin (SM). In addition to their structural function, they
play a role as signaling molecules in regulating cell differentiation, proliferation, and pro‐
grammed cell death. Mielke [89] found that high plasma levels of dihydroceramides (DHCer)
and ceramide were associated with AD progression, though results did not reach significance.
Nevertheless, higher plasma levels of SM, dihydrosphingomyelin (DHSM), SM/ceramide, and
DHSM/DHCer ratios were associated with less progression on the MMSE and ADAS-Cog with
the ratios being the strongest predictors of clinical progression. There is no current data on
MCI progression.
4.2. Genetic and transcriptomic markers
APOEε4 is the best-established genetic risk factor for AD. APOE genotyping is not recom‐
mended for the routine diagnosis of AD. However many studies have investigated whether
APOEε4 has a predictive value for progression from MCI to AD.
In a large meta-analysis, Elias-Sonnenschein [90] and co-workers found that APOEε4 is
associated with a moderately increased risk of progression from MCI to AD.
Martins [91] found that the APOEε4 genotype predicts the age of onset of AD and neuropathic
progression in a non-linear fashion. In their non-linear model, possession of an APOEε4 allele
was related to earlier and faster cognitive decline, while possession of an APOEε4 was
associated with slower decline. Homozygous APOEε4 showed faster cognitive decline than
APOEε4 heterozygotes. The linear model was less sensitive and did not detect differences
between APOEε4 homo- and heterozygotes.
Cosentino [92] also showed that the presence of at least one allele of APOEε4 was associated
with faster decline in the incident population-based AD group. However the findings could
not be extrapolated to prevalent AD in population or clinic-based samples. Hence APOEε4
influence may be more stage-dependent, with its effect on cognitive decline most evident in
the earliest stages of disease and less so in moderate to severe stages.
Other genetic markers that have been identified in genome-wide association studies (GWAS)
have not yet been shown to aid in diagnosis of AD or predict progression of disease in MCI or AD.
Unlike the static genome, the transcriptome comprises the dynamic expression of the genome
over the course of the disease. Transcriptomic, or genome-wide gene expression studies, have
been used to distinguish AD from healthy controls. One of the genes identified from tran‐
scriptomic studies is TOMM40, which has also been identified in GWAS studies [93]. We found
that TOMM40 remained significantly downregulated over three time points in a longitudinal
study (manuscript submitted for review). Transcriptomic products would ideally be used to
track the progression of disease, identify markers that predict conversion of MCI to AD, and
distinguish between fast and slow progressors. Hence this is a potential area of biomarker
development in predicting MCI conversion and rapid AD progression.
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4.3. Multiple marker arrays
Given the disappointing results achieved by single markers despite tremendous efforts, the
field has now moved towards multiple markers that are obtained through high throughput
technologies, sophisticated statistical analysis and bioinformatics. Ray [94] published a blood
plasma-based proteomic screening tool to identify patients with AD and also to identify those
likely to progress from MCI to AD. Biological analysis of the 18 proteins points to systemic
dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support. How‐
ever efforts at independent validation of Ray’s findings have been discouraging [95].
Based on current literature, no single marker has been found to be significant in all the multiple
marker arrays. Moreover one can expect that utilizing high throughput array technology, more
multiple marker arrays will appear and dominate the blood biomarker landscape. To sound
a note of caution, however, some panels may be derived from ‘over-fitting’ the dataset and
may not survive generalization and independent validation. To date, multiple marker arrays
have not been employed to study the conversion of MCI to AD and to differentiate between
fast and slow progressors. This would be a logical next step for investigation.
4.4. Summary
Plasma Aβ is an appealing biomarker since many AD interventions under investigation are
directed against Aβ. Thus an Aβ-based biomarker is attractive for those who will benefit from
such treatments. However, many studies involving various blood biomarkers have conflicting
and/or inconclusive results.
APOEε4 influence may be more stage-dependent, with its effect on disease trajectory most
evident in the earliest stages of disease and less so in moderate to severe stages. Hence it should
be included as a covariate in various clinical progression and therapeutic trials. A major
challenge is that the literature thus far has focused on the use of blood biomarkers for diagnosis
(requiring the identification of dichotomous - disease versus normal- states), which may not
be applicable to the use of such biomarkers for tracking disease progression (for which an
effective biomarker must show continuous change rather than merely being present or absent).
Nevertheless blood biomarkers should be employed in combination with clinical assessment
and neuroimaging to improve diagnostic and prognostic accuracy, especially given the
peripheral nature and ease of blood sampling.
5. Neuroimaging (Table 4)
5.1. Structural imaging
Neuroimaging is now one of the most common tools used to aid the diagnosis of AD. It is a
huge and burgeoning field and only select modalities and important studies on longitudinal
imaging are discussed here.
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Study variable Population Results  Key findings  
Predicting AD conversion in MCI subjects 
Structural Imaging 
Jack et al. [96] 55 NC, 41 MCI,  Atrophy rates of Rates of change from serial MRI studies together 
 64 AD  four structures with standard clinical/psychometric measures can 
 subjects; 1-5 (hippocampus, be used as surrogate markers of disease 
 years follow-up entorhinal progression in AD. 
  cortex, whole Atrophy rates greater among MCI converters.  
  brain, and Atrophy rates greater among AD fast progressors 
ventricle)   
      
Jack et al. [97] 133 MCI subjects 52 subjects MRI brain atrophy rate measures can be used as 
  developed AD  indicators of disease progression in a multi-site 
  (45 were APOEε4  therapeutic MCI setting. 
  carriers).   APC was greater in converters than non-converters. 
  Mean time APCs greater in APOE ε4 non-carriers.  
  to conversion APCs and changes in cognitive test performance 
  556 day in APOE uniformly correlated in expected direction (p<0.000) 
  carriers.     
Jack et al. [98] 72 aMCI 13 HC Larger ventricular APC (HR for a 1-SD increase 
 subjects, 91 HC; developed MCI 1.4, p=0.007) increased risk of AD conversion. 
 1-2 years follow- or AD; Both ventricular APC (HR for a 1-SD increase 1.59, 
 up. 39 MCI subjects p=0.001) and whole brain APC (HR for 1-SD increase 
     developed AD 1.32, p=0.009) provided additional predictive  
   information to covariate-adjusted sectional HC 
   volume at baseline about risk of AD conversion. 
   However, overlap present among those converters 
and non-converters indicate that these measures 
   are unlikely to provide absolute prognosis for 
   MCI-converters. 
Apostolova et al. [99] 20 MCI subjects 6 subjects Smaller hippocampi and specifically CA1 and 
 followed up over  developed AD subicular subfields are associated with increased 
 3 years (MCI-c), 7 risk for conversion from MCI to AD.  
  remained stable Larger hippocampal volumes and relative 
     (MCI-nc), and 7 preservation of both the subiculum and CA1 are 
improved (MCI- i). associated with cognitive stability or improvement. 
Risascher et al. [101] 339 MCI (277 62 MCI Degree of neurodegeneration of MTL structures is  
 MCI-stable, 62 developed AD the best antecedent MRI marker of imminent 
 MCI-converters)  conversion, with decreased hippocampal volume 
 subjects, 206  (left > right) being the most robust structural MRI  
 HC, 148 AD  feature. Effect sizes of hippocampus (0.6) and MTL 
 subjects  structures (0.53) comparing MCI-stable and converters. 
Querbes et al. [103] 122 aMCI (50 72 aMCI   Normalised cortical thickness can predict AD 
 stable MCI, 72 developed AD. conversion with 76% cross-validated accuracy. 
 progressive   
 MCI), 130 HC, 
 130 AD  followed  
 up over 24   
    months.  
Molecular Imaging    
Lo et al. [105] 229 normal Rates of change Amyloid deposition is an early event before 
 ,397 MCI in CSF Aβ42 hypometabolism or hippocampal atrophy, 
 and 193 AD , glucose meta- suggesting that biomarker prediction for cognitive 
 subjects bolism and change is stage dependent. 
 followed up hippocampal Positive APOE4 status accelerated hippocampal  
 3 years volume  atrophy changes in MCI and AD. 
Okello et al. [106] 31 aMCI 17 out of 31 MCI   PIB-positive MCI subjects are more likely to 
 subjects, 26 HC (55%) had develop AD than PIB-negative subjects. 
 followed up over increased  
 3 years [11C]PIB Fast converters have higher PIB retention levels at 
  retention at baseline than slower converters in anterior cingulate, 
  baseline (PIB- (p=0.027) and frontal cortex (p=0.031). 
  positive). Only 1 out of 14 PIB-negative subjects develop AD. 
  14 of these 17 7 of 17 PIB-positive MCI, APOEε4 carriers associated 
  PIB-positive MCI   with faster conversion rates (p=0.035) 
  (82%)  
  developed AD.  
  Half (47%)  
  converted to AD  
     within 1 year. 
Koivunen et al. [107] 29 MCI, 13 HC 17 MCI  Hippocampal atrophy increases and amyloid 
 followed up over developed AD  deposition changes modestly during conversion to 
 2 years  AD, suggesting dissociation between the two 
   during evolution of MCI. 
   AD converters had greater [11C]PIB retention at 
   baseline in posterior cingulate (p=0.022), putamen 
   (p=0.041), caudate nucleus (p=0.025).  
   Greater hippocampal atrophy in MCI converters at 












   baseline. 
Small et al. [108] 22 HC and 21 Increases in [18F]FDDNP PET scanning may be useful in 
 MCI followed up frontal, posterior  identifying people at risk for future cognitive 
 over 2 years cingulate, and  decline. Higher [18F]FDDNP binding at 
  global binding at baseline is associated with future decline in 
  follow-up most cognitive domains  (r = -0.31 to -0.56, 
  correlated with P = 0.05 to 0.002). 
  progression of Frontal and parietal [18F]FDDNP binding 
     memory decline  yielded highest diagnostic accuracy. ROC 
(r = -0.32 to -0.37,  0.88 (95% CI 0.72-1.00) compared with 0.68 
P = 0.03 to 0.01). (95% CI 0.45-0.91) for medial temporal binding. 
Doraiswamy et al. [109] 51 MCI, 69 HC, MCI Aβ+ and Florbetapir PET, which detects Aβ pathology, may 
 and 31 AD HC Aβ+   be helpful in identifying individuals at increased risk 
 followed up over associated with for progression to AD. 
 18 months. greater clinical Higher SUVr in MCI associated with greater decline 
  worsening on on ADAS-Cog, CDR-SB, memory measure (DSS) 
  ADAS-Cog  and MMSE (all p<0.05). 
  and CDR-SB. MCI Aβ+ had  higher risk of developing AD. 
 MCI Aβ+ associated 
 With greater  
 decline in  
 memory, DSS  
 and MMSE  
 (p < 0.05). 
Ossenkoppele et al. [110] 11 HC, 12 MCI, Global cortical [11C]PIB and [18F] FDG track molecular changes 
 and 8 AD [11C]PIB BPND in different stages of AD. 
 followed up over  is significantly  MCI subjects were found to have an increased 
 2.5 years. increased in amyloid load while AD subjects had increased 
  MCI subjects, progressive metabolic impairment. 
  but no changes [18F]FDDNP is less useful for examining disease  
  was observed in progression. 
AD subjects or Reduction in [18F]FDG uptake at follow-up  
HC. Increase  observed in AD subjects only (esp frontal, parietal, 
  most prominent   temporal lobes (all p<0.01). Changes in global  
  in lateral  [11C]PIB binding (p=-0.42, p<0.05) and cingulate 
  temporal lobe  [18F]FDG uptake (p=0.43, p<0.01) correlated 
  (p < 0.05). with changes in MMSE score over time across 
No changes in  groups but not for [18F] FDDNP binding (p=-0.18, 
global [18F] p=0.35). 
FDDNP. 
Zhang et al. [111] Meta-analysis of FDG-PET Both FDG-PET and PIB-PET are valuable 
 13 research pooled estimates: techniques for prediction of AD progression in MCI 
 studies (7 FDG- 78.7% Sn (95%  subjects. 
 PET) CI 68.7-86.6%)  
  74% Sp (95%CI 
67.0-80.3%)    
PIB-PET pooled  
estimates:    
93.5% Sn (95%  
CI 71.3-99.9%)   
  56.2% Sp (95%  
 CI 47.2-64.8%)  
Predicting rapid AD progression/ decline 
Thompson et al. [100] 12 AD subjects, Followed up Cortical atrophy occurred in a well defined 
 14 HC  3 years sequence  (temporal- frontal- sensorimotor)  
   as the disease progressed.  
   Mirroring the sequence of neurofibrillary  
   tangle accumulation observed in cross sections  
   at autopsy. 
   Left hemisphere degenerates faster (5.3 ±  
   2.3% per year in AD v.s. 0.9 ± 0.9% per year in 
   controls; p<0.029) than the right 
Kinkingnéhun et al.[103] 23 mild AD Followed up Fast decliners had a more extensive cortical atrophy 
 subjects and 18 3 years than slow decliners, especially in the medial 
 HC followed up  occipitoparietal areas (specifically precuneus,  
   Lingual gyrus and cuneus which was not yet 
   detected by clinical and neuropsychological  
   assessment.   
Functional Imaging  
Silverman et al. [107] 284 patients Progressive In patients presenting symptoms of dementia, 
 presenting dementia in  regional brain metabolism was a sensitive indicator 
 symptoms of 59% of AD. A negative PET scan indicated that 
 dementia  pathologic progression of cognitive impairment 
   during the mean 3-year follow-up was unlikely to 
   occur. Sn 93%, Sp 76%. –LR 0.1 (95% CI 0.06- 
   0.16) experiencing progressive course after a  
   single negative PET scan. 
NC = Normal Controls
MRI = Magnetic Resonance Imaging
APC = Annual percent change
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HC = Healthy Controls
SD = Standard deviation
MTL = Medial Temporal Lobe
aMCI = amnestic MCI
PIB = Pittsburgh Compound B
FDDNP = Fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile
PET = Positron Emission Tomography
MMSE =Mini Mental State Examination
Sn = Sensitivity
Sp= Specific
-LR = negative Likelihood ratio
Table 4. Neuroimaging methods in predicting AD conversion in MCI patients and rapid AD progression/ decline
With technological advances over the past three decades, MRI is now readily available and
relatively economical. Currently it is widely used as a diagnostic tool, to complement clinical
assessment and neuropsychological testing. Moreover, MRI has also been considered for
longitudinal tracking of the disease progression and to predict whether a MCI patient may go
on to develop AD, or whether an AD patient will have an indolent or rapid course. Advances
in technology have led to automated data-driven methods, such as automated measurement
of whole brain volume over time, voxel-based morphometry (VBM), deformation-based
morphometry (DBM) and analysis of cortical thickness. These technologies ameliorate the
previous problems associated with manual measurement, inter-rater reliability and difficulties
in cross-study comparisons.
In a seminal paper, Jack [96] studied annualized changes in volume of four structures in serial
MRI studies: hippocampus, entorhinal cortex, whole brain and ventricles of normal, MCI and
AD subjects. All four atrophy rates were greater among MCI-converters compared to non-
converters and fast-progressors versus slow progressors. Although the differences in atrophy
rates have been replicated consistently in several follow-up studies [97,98], given the overlap
among those who did and did not convert, the authors cautioned that these measures were
unlikely to provide absolute prognostic information for individual patients.
Using hippocampal volumetry, a prospective longitudinal cohort study found that greater
atrophy in the CA1 hippocampal and subicular subfields predicted MCI conversion, whereas
larger hippocampal volumes predicted cognitive stability and/or improvement [99].
Employing a 3-dimensional cortical mapping approach, Thompson [100], demonstrated a
temporal-frontal-sensorimotor sequence of cortical atrophy with AD progression in a longi‐
tudinal series of 12 AD subjects, where left brain was found to degenerate faster than right.
Employing VBM technique, Risacher [101] found that AD and MCI converters demonstrated
high atrophy across regions as compared to HC in global and hippocampal grey matter (GM)
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density, hippocampal and amygdalar volumes, and cortical thickness values from entorhinal
cortex and other temporal and parietal lobe regions. MCI-stable showed intermediate atrophy.
Degree of atrophy of medial temporal structures, especially the hippocampi, was found to be
the best antecedent MRI marker of imminent conversion.
A separate study also showed that occipitoparietal (specifically precuneus, lingual gyrus and
cuneus) atrophy at baseline better anticipated the rate of progression (fast decliners from slow
decliners) over 3 years compared to clinical and neuropsychological assessment [102].
Cortical thickness is another measure of interest in structural neuroimaging where a normal‐
ized thickness index was computed using a subset of these regions, namely the right medial
temporal, left lateral temporal and right posterior cingulate. Normalized thickness index at
baseline differed significantly among all the four diagnosis groups (HC, stable MCI, progres‐
sive MCI and AD). Furthermore, normalized thickness index also correctly predicted evolution
to AD for 76% of aMCI subjects after cross-validation [103].
5.2. Functional and molecular imaging
There are many functional imaging studies for AD though only a few specifically investigate
longitudinal progression of MCI and AD using Fluorodeoxyglucose (18F) (FDG)-Positron
Emission Tomography (PET) [104].
Lo [105] found that the rate of change of glucose metabolism and hippocampal volume
accelerated as cognitive function deteriorated. Moreover, glucose metabolic decline and
hippocampal atrophy were significantly slower in subjects with normal cognition compared
to those with MCI or AD. Positive APOE4 status was also associated with accelerated hippo‐
campal atrophy.
Molecular imaging utilizes small molecule ligands that bind with nanomolar affinity to
amyloid and enters the brain for imaging with PET. It is a measure to detect and quantify
cerebral beta-amyloidosis. It should be noted that besides AD, there are other disease condi‐
tions that may have cerebral Aβ.The most commonly used ligand is the carbon-11(11C)-based
Pittsburgh compound B (PIB), which binds specifically to fibrillar Aβ but exhibits no demon‐
strable binding to neurofibrillary tangles. However, fluorine-18 (18F)-based tracers, e.g. 2-(1-
{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile
([(18)F]FDDNP) have a considerably longer half-life compared to [11(C)]PIB and some types
have been shown to also bind to neurofibrillary tangles.
Okello [106] showed that PIB-positive subjects with MCI are significantly more likely to
convert to AD than PIB-negative ones. A separate longitudinal study showed that hippocam‐
pal atrophy and amyloid deposition (in posterior cingulate, lateral frontal cortex, temporal
cortex, putamen and caudate nucleus) seem to dissociate during the evolution of MCI, the
atrophy increasing clearly and [(11)C] PIB retention changing modestly when conversion to
AD occurs [107]. Using [(18)F]FDDNP PET, higher baseline binding was associated with future
decline in most cognitive domains. Specifically, frontal and parietal [(18)F]FDDNP binding
yielded the greatest diagnostic accuracy in identifying MCI-converters versus non-converters
[108]. With 18F florbetapir (18F-AV-45) tracer, baseline Aβ + scans were associated with greater
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clinical worsening on the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and Clinical
Dementia Rating-sum of boxes (CDR-SB). In MCI, Aβ + scans were also associated with greater
decline in memory, Digit Symbol Substitution (DSS) and MMSE. Aβ + MCI subjects again
tended to convert to AD at a higher rate than Aβ- subjects [109].
In a seminal comparison study of three modalities [110], using [(11)C]PIB, [(18)F]FDDNP and
[18F]FDG, there was a significant increase in global cortical [(11)C]PIB binding (most promi‐
nent in the lateral temporal lobe) in MCI patients, but no changes in AD patients or controls.
Interestingly, [(18)F]FDDNP did not show any changes in global binding potential. Moreover,
changes in global [(11)C]PIB binding and posterior cingulate [(18)F]FDG uptake were corre‐
lated with changes in MMSE score over time across groups, but not with [(18)F]FDDNP
binding. Hence it was postulated that [(11)C]PIB and [(18)F]FDDNP track molecular changes
in different stages of AD. There was an increased amyloid load in MCI patients and progressive
metabolic impairment in AD patients. The authors opined that [(18)F]FDDNP was less useful
for examining disease progression.
To estimate the diagnostic accuracy of FDG-PET and PIB-PET for prediction of short-term
conversion to AD in patients with MCI, Zhang [111] and co-workers performed a meta-analysis
undertaken with a random-effects model. Overall diagnostic accuracy determined for both
FDG-PET and PIB-PET suggests that they are potentially valuable techniques for prediction
of progression in patients with MCI. Both have their advantages and their combined use is a
promising option.
Villain et al recently published a longitudinal PIB study (testing conducted 18 months apart),
showing a significant increase in amyloid-β accumulation in both PIB-positive and negative
subjects (significantly higher in PIB-positive individuals) with a bimodal distribution of
individual rates of neocortical amyloid- β accumulation [112].
5.3. Summary
MRI volumetry and brain atrophy rates have fairly good diagnostic and predictive value in
MCI subjects. Longitudinal data on brain atrophy rates with disease progression are available
and hence, can be used for monitoring disease progression in clinical trials. The limitations of
structural neuroimaging as a biomarker include problems with the accurate delineation of
regions of interest and lack of standardization of imaging and measurement techniques,
making it difficult to compare data across the different institutions out of Europe, North
America and Australia (all of which have their unified imaging consortiums). The advent of
automated data-driven innovations for structural imaging holds promise. FDG-PET appears
to be the leading candidate among the functional neuroimaging modalities, with available
evidence for MCI diagnosis, prediction of MCI-converters and longitudinal data in monitoring
serial progression. To date, [(11]C] PIB is the most extensively studied PET amyloid tracer,
although 18F florbetapir proves to be an attractive alternative given the longer half-life. There
is emerging evidence for amyloid imaging in the diagnosis of preclinical AD. From the
standpoint of clinical trials of anti-amyloid therapy, in-vivo amyloid imaging pre-treatment
allows selection of patients with demonstrable cerebral Aβ loads; repeated imaging during
ongoing treatment allows detection of decrease in insoluble Aβ load in response to amyloid-
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clearing drugs such as immunotherapy. Amyloid imaging needs to be more practically
accessible and affordable before it can be transferable to the clinical diagnostic routine.
6. Combinational biomarkers
Many of the aforementioned biomarker modalities are not separate discrete entities but have
an effect on each other. For example, the association of hypertension with CSF tau and
ptau-181, was found to be modified by APOEε4 phenotype, where hypertension is directly
related to tau pathology (and not Aβ42) in APOEε4 homozygous carriers [113]. Elevated CSF
t-tau and p-tau in presence of APOEε4/ε4 genotype has also been shown to influence faster
AD progression in MCI subjects [114].
For the identification of MCI-converters, various literature showing combination biomarkers
have been published. They include looking at clinical measures (such as cognitive or neuro‐
psychological tests) in combination with CSF biomarkers [115], neuroimaging measures [116,
117], or in combination with both CSF and neuroimaging measures [118-119].
A combination of CSF and neuroimaging biomarkers [120-4] has found improved predictive
accuracy of MCI-converters, supported by slope analyses of annual cognitive decline [120].
Okamura showed that a high ratio between cerebrospinal fluid (CSF) tau and posterior
cingulate perfusion on SPECT is useful in identifying MCI converters [125]. Using a machine-
learning approach (support vector machines), Furney et al examined the utility of adding
cytokine and neuroimaging biomarkers to conventional measures, and found that the combi‐
nation of cytokine and neuroimaging with clinical and APOEε4 genotype improved accuracy
[126]. Recent studies have also looked at multimodal neuroimaging techniques to predict MCI
progression [127-129].
Other recent studies have used endophenotype-based approach and found single nucleotide
polymorphism (SNP) such as rs1868402 to have strong, replicable association with
CSFptau181 association with rate of AD progression [130].
7. Conclusion and future directions
Clinical criteria alone, often subjective and dependent on clinical judgment, are insufficient to
identify the pre-clinical stages of AD accurately. This has prompted the past decade-long
intensive research into the use of more objective neuroimaging and biochemical markers to
either replace, or complement, clinical approaches to facilitate an early and accurate diagnosis
of the illness [131,132]. The chapter thus far details the rationale (most evident from Table 1)
for the combined approach of clinical measures with other biomarkers in predicting AD
progression; but in the earlier stages (prodromal and especially preclinical AD stages),
biomarkers would play an increasingly important role. Combination biomarker approaches
appear to be superior to a single biomarker approach, with the recent focus of researchers being
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Subjects    Follow-up (years)   Biomarker     Results   
 
MCI (n=8)          1  CSF p-tau231               MCI:  5.0; NC: 3.0 * 
NC  (n=10)  CSF Aβ40                     MCI:  4.0; NC: 8.0             
[70]   CSF Aβ42                     MCI: 4.0; NC: 2.0  
 
MCI (n=7)          2  CSF p-tau231               MCI: 2.0; NC: 20.0 * 
NC (n=9)   CSF Aβ40      MCI: 0.5; NC:  3.5                     
[71]   CSFAβ42                      MCI: 0.35; NC: 1.5 
 
 
MCI (n=62)        2  CSF isoprostane  NC:-1.9; MCI:-0.4; AD: 5.0 ** 
AD (n-68)   CSF neurofilaments light NC:-0.18; MCI:-0.79; AD: -0.96 
NC (n=24)  CSF Aβ40  NC: 0.61; MCI:0.28; AD:0.43  
[72]   No change in Aβ42 or p-tau 181. 
 
MCI (n=57)        3  CSF Aβ42   MCI(stable): 3.42, MCI (converters):0.78, AD:-11.9** 
AD (n=56) [65]  CSF tau   MCI(stable):19.7, MCI(converters):17.4, AD: 0.55 
NC (n=8)   CSFp-tau   MCI(stable):1.24, MCI(converters):-0.21, AD: -2.2 
   CSFAβ42/tau   MCI(stable):-0.54.MCI(converters):-0.4,AD: -0.008 
   CSFAβ42/ptau  MCI(stable):-0.19, MCI(converters):-0.07,AD:0.18 
 
NC (n=55)         1.2-2.4 Hippocampus*  MCI (stable):-4.4,MCI(converters):-7.8, AD slow -9.4, 
MCI (n=41)      AD fast -15.4  
AD (n=64) [99]  Entorhinal cortex  MCI(stable):-15.9, MCI(converters):-16.0, AD slow-20.5, 
       AD fast -22.7 
Whole brain  MCI (stable):-0.8, MCI (converters):-2.5, AD slow -2.4, 
       AD fast -3.6 
   Ventricle    MCI (stable):0.8, MCI(converters):1.8, AD slow -6.5,  
       AD fast 1.9      
MCI (n=131)     3  Hippocampus *  MCI (converters) -6.78; MCI (non-converters) -3.86 
[101]   Entorhinal cortex  MCI (converters) -15.08 ; MCI (non-converters) -8.32 
   Whole brain  MCI (converters) -0.88 ; MCI (non-converters) -0.36 
   Ventricle   MCI (converters) 5.66 ; MCI (non-converters) 3.33 
 
MCI (n=72)       1-2  Hippocampus *  -3.3 (2.7) 
[104]   Entorhinal cortex  -7.0 (4.3) 
   Whole brain  -0.7 (1.0) 
   Ventricle   3.3 (2.3) 
 
AD (n=32)        1.5  PiB-PET   AD: PiB-(acc) +0.06; PiB+(acc) +0.05; PiB 
MCI (n=49)  (neocortical PiB rate         (non-acc) -0.01 
NC (n=103)                 of change)  MCI: PIB-(acc) +0.04; PiB-(non-acc) -0.001; 
[116]   (SuVRpons/year) *           PiB+ (acc) +0.04; PiB (non-acc) -0.01 
      HC: PiB-(acc)+0.03; PiB- (non-acc) -0.01; 
             PiB+(acc) +0.04; PiB+ (non-acc) -0.004            
NC (n=210)      2  CSF Aβ42    NC: -0.94; MCI: -1.4; AD; -0.1 * 
MCI (n=357)  CSF tau   NC: 3.45; MCI: 2.34; AD: 1.24  
AD (n=162)  PIB   NC: 0.098; MCI: -0.008; AD: -0.004  
[135]   FDG-PET   NC: -177; MCI: 752; AD: 2993   
   Hippocampus  NC: -40; MCI: -80; AD: -116   
   Ventricles   NC: 848; MCI: 1551; AD: 2540  
   ADAS-Cog total  NC: -0.54; MCI: 1.05; AD: 4.37  
   MMSE   NC: 0.0095; MCI:-0.64; AD: -2.4  
   CDR-SB   NC: 0.07; MCI 0.63; AD: 1.62  
   RAVLT (5 trial total)  NC: 0.29; MCI: -1.37; AD: -3.62   
  
* expressed as % change per year compared to baseline values
** expressed as annual change β
MCI = Mild Cognitive Impairment
NC = Normal Controls
AD = Alzheimer’s Disease
CSF = Cerebrospinal fluid
PIB = Pittsburgh Compound B
FDG-PET = Fluorodeoxyglucose (18F)-Positron Emission Tomography
MMSE = Mini Mental State Examination
CDR-SB = Clinical Dementia Rating – Sum of Boxes
RAVLT = Rey Auditory Verbal Learning Tes
Table 5. Longitudinal biomarker studies
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on multimodal approach using various systems biology and multivariate modeling methods.
Additionally, multi-site prospective studies, such as the Alzheimer’s Disease Neuroimaging
Initiative (ADNI), allow for global summary of results and patterns of change observed in
clinical measures and candidate biomarkers [133] (Table 5). It must also be highlighted that
some of the heterogeneity of biomarker findings thus far is related to the different periods of
follow-up and hence AD conversion rates in MCI subjects.
The dynamic biomarker model, in the AD pathological cascade first proposed by Jack in 2010
[134], has been an area of intense interest. However, this inverse relationship between fibrillar
amyloid plaque burden (on PIB imaging) and corresponding decrease in CSF Aβ42 and
elevated tau, has led to the simplistic interpretation that the AD pathological cascade is purely
driven by the amyloid cascade (Figure 1). This is partly due to extrapolation from cross-
sectional studies, where in fact, longitudinal studies are required to determine the temporal
order of the appearance of various pathogenic processes involved in this complex disease.
Storandt et al [135] has recently demonstrated in a community cohort that CSF Aβ42 and tau
were minimally correlated, suggesting that they represent independent processes. Addition‐
ally, they accounted for only 60% of variance on PIB imaging, suggesting that a third process
may be related to brain atrophy or plaque formation [136].
In addition, understanding longitudinal biomarker change allows its potential inclusion in
clinical trials, with recent studies advocating the use of neuroimaging biomarkers [137,138],
CSF biomarkers [139] and/or combination biomarkers [137,140] to boost the power of clinical
trials and decrease sample size in MCI trials. An integrated analyses approach using patient
(age) severity- and disease-related (severe baseline cognitive, global or behavioural status)
factors in established AD has been shown, with the potential of symptomatic AD therapy, to
decrease likelihood of faster decline [141].
Further work on biomarkers is important because of their multiple potential roles. Biomarkers
have the potential to be used as a prognostic tool for the prediction of AD conversion in MCI
subjects and rapid AD progression, with translation into clinical practice by using a most
practical algorithm, and as a diagnostic tool in prodromal/ preclinical stages of AD. Biomarkers
may also lead to a deeper understanding of the complex pathogenesis of AD disease –
including stage-specific and stage-independent processes. There is also currently an unfulfil‐
led potential in biomarker-enriched clinical trials and the use of biomarkers in preclinical AD,
especially in the advent of newer therapeutic targets. Finally there is also potential to extrap‐
olate biomarker findings ‘backwards’ into the earliest stages of disease so that we may be able
to identify those at risk and consider instituting interventions. This would enable earliest
therapeutic intervention for at-risk subjects most amenable to disease-modifying treatments,
and exclude those for whom the possible risks from investigational treatment would be more
difficult to justify. At the very least, it would identify those who might benefit most from
intensive monitoring and management of clinical factors, e.g. blood pressure, diabetes and
lipids, and also non-invasive interventions, e.g. cognitive training. This vital work can only
been done through multi-center studies and standardized evaluation techniques using various
systems biology and statistical modeling approaches.
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